Caribou Biosciences, Inc. experienced a 45% share price decline after presenting puzzling results for their product candidate CB-010 in a Phase 1 clinical trial. CB-010 showed limited efficacy in ...

HLA compatibility is considered the key criterion for selecting donors for allo-HSCT. DKMS study data presented at the DGHO Annual Meeting 2025 in Cologne indicate the biological age of donors has a ...

Jayme Locke, MD MARCO ISLAND, Fla.—The transplant community may want to rethink the importance of HLA mismatches when considering live donor kidney transplants, according to new data presented here at ...

ORLANDO -- Stem-cell transplants with mismatched unrelated donors (MMUDs) beyond a single HLA locus (<7/8) had 1-year survival similar to better-matched donors, suggesting significant potential to ...

HLA matching in bone marrow transplantation has an important role in determining successful outcome. However HLA typing of both potential related and unrelated donors can be both time-consuming and ...

The selection of suitable donors is crucial for the long-term recovery of patients after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Primarily, the transplantation from a ...

Analyses of two large stem-cell transplant registries yielded conflicting results about the effect of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis on the ...

Anil Paramesh, MD De-emphasis on HLA matching could lead to worse outcomes in highly sensitized patients, FORT LAUDERDALE, Fla.—Highly sensitized renal transplant recipients can have excellent ...

Please provide your email address to receive an email when new articles are posted on . Patients who received stem cell grafts from unrelated donors matched at as few as 4/8 HLA markers achieved ...

Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform ...